Oxaliplatin Fresenius Kabi (Oxaliplatin)

Oxaliplatin is a platinum‑based chemotherapeutic agent used primarily within colorectal cancer treatment pathways.

• Colorectal cancer: enhances tumor response when combined with fluoropyrimidine‑based regimens.
• Gastric cancer: contributes to disease control as part of combination chemotherapy.
• Pancreatic cancer: used in select protocols to improve progression‑free survival.
• Adjuvant therapy: administered after surgical resection to reduce recurrence risk.
• Metastatic disease: employed to shrink tumors and alleviate symptoms in advanced stages.

• Oxaliplatin forms reactive platinum complexes that covalently bind to DNA, creating intra‑ and interstrand cross‑links that impede DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing tumor cells while sparing most normal tissues.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal upset during infusion.
• Peripheral neuropathy: tingling or numbness in hands and feet, often dose‑related.
• Diarrhea: watery stools that may require supportive care.
• Fatigue: generalized tiredness affecting daily activities.
• Myelosuppression: reduced blood cell counts, increasing infection risk.
• Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Acute neurotoxicity: sudden onset of muscle cramps or difficulty breathing.
• Thrombotic events: blood clot formation in veins or arteries.
• Severe myelosuppression: profound neutropenia or thrombocytopenia.
• Renal impairment: acute kidney injury requiring monitoring.
• Cardiac arrhythmias: irregular heart rhythms observed during infusion.

When handling Oxaliplatin, clinicians should observe specific safety measures and patient monitoring protocols.

• Renal function: assess baseline creatinine and adjust therapy if impairment is present.
• Hepatic function: monitor liver enzymes before each cycle.
• Neuropathy risk: evaluate pre‑existing peripheral neuropathy and adjust dose as needed.
• Hematologic status: perform complete blood counts regularly to detect myelosuppression.
• Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with obstetric specialist.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin can interact with several concomitant medications, influencing efficacy or toxicity.

Major Interactions (Avoid)

• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of renal damage.
• Highly protein‑bound drugs (e.g., warfarin): may alter plasma concentrations.

Moderate Interactions (Monitor Closely)

• Antiemetics (e.g., ondansetron): may affect oxaliplatin clearance.
• CYP450 inducers (e.g., rifampicin): potential reduction in drug exposure.
• Antioxidants (e.g., vitamin C high doses): could diminish platinum‑DNA binding.
• Radiotherapy: concurrent use may enhance neurotoxicity.
• NSAIDs: may exacerbate renal toxicity when combined.